Embecta (EMBC) Projected to Post Earnings on Friday

Embecta (NASDAQ:EMBC) is projected to post its quarterly earnings results before the market opens on Friday, February 14th. Analysts expect Embecta to post earnings of $0.45 per share for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a negative return on equity of 18.54% and a net margin of 6.97%. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Trading Down 2.6 %

Shares of Embecta stock opened at $17.73 on Friday. The business has a 50-day moving average price of $19.70 and a two-hundred day moving average price of $16.52. Embecta has a 1-year low of $9.93 and a 1-year high of $21.48. The company has a market cap of $1.03 billion, a P/E ratio of 13.13, a PEG ratio of 0.97 and a beta of 1.20.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th were issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date was Friday, December 6th. Embecta’s payout ratio is 44.44%.

Analyst Upgrades and Downgrades

EMBC has been the topic of several analyst reports. Morgan Stanley raised Embecta from an “underweight” rating to an “equal weight” rating and lifted their target price for the company from $13.00 to $20.00 in a research report on Monday, December 2nd. BTIG Research raised Embecta from a “neutral” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Wednesday, November 27th.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.